94169-64-9

Basic information

• Product Name: Benzaldehyde, 3,5-bis(1-methylethoxy)-
• CAS NO: 94169-64-9
• Molecular Formula: C13H18O3
• Molecular Weight: 222.284
• Mol File: 94169-64-9.mol

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 3,5-bis(1-methylethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 3,5-bis(1-methylethoxy)-(94169-64-9)
• EPA Substance Registry System: Benzaldehyde, 3,5-bis(1-methylethoxy)-(94169-64-9)

Safety Data

• Hazardous Substances Data: 94169-64-9(Hazardous Substances Data)

Upstream product

• 94169-63-8 (3,5-diisopropoxyphenyl)methanol 
• 26153-38-8 3,5-dihydroxybenzaldehyde 
• 75-26-3 isopropyl bromide 
• 951776-82-2 C₁₆H₂₄O₄ 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 29654-55-5 5-(hydroxymethyl)benzene-1,3-diol 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 94169-62-7 methyl 3,5-di-isopropoxybenzoate 
• 75-30-9 2-iodo-propane 

Downstream Products

• 951776-59-3 C₂₁H₂₄O₅ 
• 94169-68-3 methyl 2'-iodo-3',5'-di-isopropoxy-4,5,6-trimethoxystylbene-3-carboxylate 
• 94169-69-4 methyl 2'-iodo-3',5'-di-isopropoxy-4,5,6-trimethoxystylbene-3-carboxylate 
• 1453904-29-4 (Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylaldehyde 
• 1453904-32-9 (Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)prop-2-en-1-ol 
• 1453904-33-0 (E)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)prop-2-en-1-ol 
• 1453904-34-1 (E)-methyl 3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylate 
• 1453904-37-4 (Z)-methyl 3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylate 
• 1453904-35-2 (Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylic acid 
• 1453904-36-3 (Z)-3-(2-chloro-3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylic acid 
• 1453904-20-5 (Z)-3-(3,5-diisopropoxyphenyl)-2-(4-hydroxyphenyl)acrylonitrile 
• 1453904-21-6 (Z)-3-(3,5-diisopropoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile 
• 1228424-91-6 trans-3,5-diisopropoxy-4-methoxystilbene 
• 216700-54-8 2-(3,5-Diisopropoxy-phenyl)-5,7-diisopropoxy-chroman-4-one 

Relevant articles and documents

Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2

Resveratrol (3,5,4′-trihydroxylstilbene) has been proposed to elicit a variety of positive health effects including protection against cancer and cardiovascular disease. The highest affinity target of resveratrol identified so far is the oxidoreductase enzyme quinone reductase 2 (QR2), which is believed to function in metabolic reduction and detoxification processes; however, evidence exists linking QR2 to the metabolic activation of quinones, which can lead to cell toxicity. Therefore, inhibition of QR2 by resveratrol may protect cells against reactive intermediates and eventually cancer. With the aim of identifying novel inhibitors of QR2, we designed, synthesized, and tested two generations of resveratrol analogue libraries for inhibition of QR2. In addition, X-ray crystal structures of six of the resveratrol analogues in the active site of QR2 were determined. Several novel inhibitors of QR2 were successfully identified as well as a compound that inhibits QR2 with a novel binding orientation.

BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES

This invention relates to compounds of the formula wherein A, R1 to R3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PYRIMIDINE AND QUINAZOLINE DERIVATIVES

This invention is concerned with compounds of the formula ( l ) wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES

This invention is concerned with compounds of the formula wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES

This invention relates to 4,4-disubstituted piperidine derivatives of the formula wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceuti

ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES

This invention relates to compounds of the formula wherein X is O or NR8, Y is CR7 or N, and R1 to R8 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES

This invention is concerned with compounds of the formulaand pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES

This invention relates to 4,4-disubstituted piperidine derivatives of the formula (I) wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmac

Stereo- and regioselective glycosylates to the Bis-C-arylglycoside of kidamycin

In explorations toward the total synthesis of the antitumor anthrapyran natural product kidamycin, the regioselective introduction of aminosugars angolosamine and vancosamine as C-arylglycosides has been accomplished onto hydroxylated anthrapyran aglycone

Design of potent PPARα agonists

Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPARα agonists. Optimum PPARα potency and selectivity were obtained with substituents having van der Waals volume around 260. Compound 6 had a PPARα potency of 0.002 μM and a selectivity ratio to PPARγ and PPARδ of 410 and 2000, respectively.